CHST7 and acute lymphoblastic leukemia: CHST2 and CHST7 were used as biomarkers for pediatric high-risk B-precursor acute lymphoblastic leukemia, and patients with high CHST2 and CHST7 expression had poor 4-year relapse-free survival rates [20].